Key result
LMWH prevents hemodialysis circuit clotting while causing less bleeding and thrombocytopenia than UFH.
Why the study?
Unfractionated heparin has variable biological activity risking under and over anticoagulation, motivating the development of low molecular weight heparins for hemodialysis.
Do low molecular weight heparins improve reliability and safety compared to unfractionated heparin in patients undergoing hemodialysis?
Do low molecular weight heparins improve reliability and safety compared to unfractionated heparin in patients undergoing hemodialysis?
LMWHs offer a more reliable and safer anticoagulation alternative to UFH for routine outpatient hemodialysis.
Answers are grounded in this paper and cite their sources.
LMWHs may reduce bleeding versus UFH in hemodialysis; leaves open need for contemporary randomized confirmation.
Unfractionated heparin (UFH) is the most commonly used anticoagulant for hemodialysis worldwide. However, UFH comprises a series of different molecules with variable biological activity, thus risking under and over anticoagulation. As such, low molecular weight heparins (LMWHs) were developed to improve reliability. LMWHs are now established in clinical practice and have been proven to be effective in preventing extracorporeal circuit clotting, but also safer with fewer reported bleeding episodes and less heparin induced thrombocytopenia than UFH. As with UFH, most centers simply adjust the dose of LMWHs by clinical inspection of the extracorporeal circuit for thrombus, and bleeding times post-fistula needle removal. Despite potentially higher drug costs, LMWHs have become the anticoagulant of choice in Europe for routine outpatient hemodialysis sessions, due to their ease of administration and reliability of clinical effect.
No takes yet. Share an insight, caveat, or question.
Andrew Davenport (2013) conducted a review in Hemodialysis. Low molecular weight heparins (LMWHs) vs. Unfractionated heparin (UFH) was evaluated. Low molecular weight heparins are effective in preventing extracorporeal circuit clotting during hemodialysis and are safer with fewer bleeding episodes and less thrombocytopenia than UFH.
Synapse has enriched 10 related papers. Consider them for comparative context: